The litigation, Cheng v. Erasca, Inc., centers on allegations that executives failed to disclose the precarious nature of the company's preclinical data for ERAS-0015. This molecular glue, intended to treat RAS-mutated solid tumors, reportedly relied on flawed comparisons to Revolution Medicines, Inc. Plaintiffs claim these misleading benchmarks exposed Erasca to significant patent and trade secret infringement risks, undermining the validity of earlier positive public statements regarding the drug's development.
Erasca Faces Securities Lawsuit Over Alleged Misleading ERAS-0015 Data
Investors who lost over $100,000 in Erasca securities between January 2025 and April 2026 face an August 10 deadline to apply as lead plaintiffs in a pending class action. The lawsuit, filed in the Southern District of California, accuses the company of obscuring critical risks associated with its experimental drug pipeline.
Legal counsel from Kahn Swick & Foti, LLC, is currently reviewing options for shareholders affected by the alleged omissions. Those seeking to participate in the proceedings or evaluate their legal standing are encouraged to contact the firm or utilize the ClaimsFiler portal before the court-mandated August 10 cutoff for lead plaintiff applications.
Comments (0)
No comments yet. Be the first!